Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 8
Submit an article Journal homepage
363
Views
4
CrossRef citations to date
0
Altmetric
Letters to the Editor

DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia

Preetesh JainDepartment of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA;
,
Srdan VerstovsekDepartment of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA;
,
Wei WangDepartment of Hematopathology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA;
,
Sanam LoghaviDepartment of Hematopathology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA;
,
Harrys A. TorresDepartment of Infectious Diseases, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA
,
Zeev EstrovDepartment of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA;
,
Keyur P. PatelDepartment of Hematopathology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA;
&
Naveen PemmarajuDepartment of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA; Correspondence[email protected]
 show all
Pages 1969-1973 | Received 29 Sep 2015, Accepted 17 Nov 2015, Published online: 24 Dec 2015

References

  • Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24:1574–1579.
  • Gangat N, Strand J, Li CY, et al. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol. 2007;138:354–358.
  • Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27:1874–1881.
  • Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124:2507–2513. quiz 2615.
  • Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23:2224–2232.
  • Zhang SJ, Rampal R, Manshouri T, et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood. 2012;119:4480–4485.
  • Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123:2220–2228.
  • Quintas-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood. 2013;122:893–901.
  • Rao N, Butcher CM, Lewis ID, et al. Clonal and lineage analysis of somatic DNMT3A and JAK2 mutations in a chronic phase polycythemia vera patient. Br J Haematol. 2012;156:268–270.
  • Portell CA, Sekeres MA, Rogers HJ, Tiu RV. De novo polycythaemia vera arising 5 years following acute myeloid leukemia remission: suggestion of a chemotherapy resistant JAK2 clone. Br J Haematol. 2012;157:266–267.
  • Belotti A, Doni E, Elli E, et al. Development of polycythemia vera after chemotherapy-induced remission of acute myeloid leukemia: a case report. Acta Haematol. 2011;126:52–53.
  • Youk HJ, Cho CH, Lee JH, et al. A rare case of polycythemia vera following acute undifferentiated leukemia remission. Ann Lab Med. 2014;34:469–470.
  • Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368:22–33.
  • Hazani A, Tatarsky I, Barzilai D. Prolonged remission of leukemia associated with polycythemia vera. Cancer. 1977;40:1297–1299.
  • Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27:5418–5424.
  • Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391–2405.
  • Stegelmann F, Bullinger L, Schlenk RF, et al. DNMT3A mutations in myeloproliferative neoplasms. Leukemia. 2011;25:1217–1219.
  • Patel KP, Newberry KJ, Luthra R, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015;126:790–797.
  • Hornstein E, Shomron N. Canalization of development by microRNAs. Nat Genet. 2006;38:S20–S24.
  • Ortmann CA, Kent DG, Nangalia J, et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015;372:601–612.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.